ALK and non-small cell lung carcinoma: Small-molecule tyrosine kinase inhibitors (TKIs) that target ALK have been introduced in the last 10 years, leading to improved progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) in patients with ALK-rearranged NSCLC in various clinical trials [9].